SCHEMBL4526069

SCHEMBL4526069

O=C(Nc1cccc(CS)c1)c1n[nH]c2ccccc12

nearest known ligand 0.75

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CSNK2A1 P68400 5/20 0.75
CDK5 Q00535 1/20 0.69
CDK5R1 Q15078 1/20 0.69
FLT3 P36888 7/20 0.68
MAP4K1 Q92918 2/20 0.68
CDK2 P24941 3/20 0.67
CCNA2 P20248 1/20 0.67
CCNA1 P78396 1/20 0.67
ITK Q08881 2/20 0.57
ACKR3 P25106 1/20 0.55
IDO1 P14902 1/20 0.54
NPC1 O15118 1/20 0.54
ALDH1A1 P00352 1/20 0.54
RAB9A P51151 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL952937 0.89 FLT3 (0.77) CSNK2A1CDK5CDK5R1FLT3MAP4K1
SCHEMBL23657708 0.82 CSNK2A1 (0.67) CSNK2A1CDK5CDK5R1FLT3MAP4K1
SCHEMBL30398090 0.81 FLT3 (1.00) CSNK2A1FLT3MAP4K1CDK2CCNA2
SCHEMBL951125 0.81 FLT3 (1.00) CSNK2A1FLT3MAP4K1CDK2CCNA2
SCHEMBL30695135 0.81 FLT3 (0.73) CSNK2A1CDK5CDK5R1FLT3MAP4K1
SCHEMBL30695136 0.81 FLT3 (0.73) CSNK2A1CDK5CDK5R1FLT3MAP4K1
SCHEMBL953507 0.81 FLT3 (0.73) CSNK2A1CDK5CDK5R1FLT3MAP4K1
SCHEMBL30695138 0.81 FLT3 (1.00) CSNK2A1CDK5CDK5R1FLT3MAP4K1
SCHEMBL30695127 0.81 FLT3 (0.73) CSNK2A1CDK5CDK5R1FLT3MAP4K1
SCHEMBL29176630 0.81 FLT3 (0.73) CSNK2A1CDK5CDK5R1FLT3MAP4K1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7482342-B2 Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors SANOFI-AVENTIS (FR) 2009-01-27 US disclosed
US-20060004000-A1 Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors SANOFI-AVENTIS (FR) 2006-01-05 US disclosed
EP-1549620-A1 INDAZOLECARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF AS CDK1, CDK2 AND CDK4 INHIBITORS Sanofi-Aventis (FR) 2005-07-06 EP disclosed
WO-2004031158-A1 INDAZOLECARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF AS CDK1, CDK2 AND CDK4 INHIBITORS SANOFI-AVENTIS (FR) 2004-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004000-A1 Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors CDK2, CDK1, CDK4 CSNK2A1 62/4885CDK5 35/4885CDK5R1 49/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.